Latest News

Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL
Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL

December 10th 2023

In the final analysis of the phase 2 ELM-2 trial, odronextamab monotherapy showed encouraging efficacy, with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

Auto-HCT Improves PFS, Relapse Rates in Relapsed LBCL Subset During Complete Response
Auto-HCT Improves PFS, Relapse Rates in Relapsed LBCL Subset During Complete Response

December 10th 2023

Study of Golidocitinib Finds Favorable Efficacy in Pretreated PTCL
Study of Golidocitinib Finds Favorable Efficacy in Pretreated PTCL

December 10th 2023

Outpatient CAR T-Cell Therapy Process Improved by Virtual Care Platform
Outpatient CAR T-Cell Therapy Process Improved by Virtual Care Platform

December 10th 2023

Zanubrutinib Induces Sustained PFS Benefit in Relapsed/Refractory CLL/SLL
Zanubrutinib Induces Sustained PFS Benefit in Relapsed/Refractory CLL/SLL

December 10th 2023

Video Series
Video Interviews
Podcasts

More News